Abstract: The present disclosure relates in certain aspects, to compositions and methods for stabilizing analytes of interest in an oral fluid. In another aspect, the present disclosure relates to sequestering and/or isolating analytes of interest from an oral fluid. In another aspect, the present disclosure relates to methods of detecting or quantifying the amount of an analyte of interest in an oral fluid. In another aspect, the present disclosure relates to devices and kits for the same. In certain embodiments, the analytes of interest are drugs of addiction, including tetrahydrocannabinol (THC).

Abstract: Provided herein are devices and methods for treating inflammation and pain of articular joints (e.g., the knee). An implantable device includes an elongate body extending from a proximal end to a distal end, a flange disposed at the proximal end, a bore extending from an opening at the proximal end into the elongate body, one or more fixation members disposed on an outer surface of the elongate body, and a payload (e.g., a drug-polymer core) having a therapeutic agent disposed within the bore. The payload has a substantially constant surface area on an exposed portion throughout elution of the therapeutic agent after the implantable device is implanted in a body. The therapeutic agent is configured to elute using zero-order kinetics, constantly and continuously at an amount that is above a predetermined lower threshold and does not exceed a predetermined upper threshold unlike a pulse-dose injection.

Abstract: A drug delivery implant may include an implant body and a core comprising a pharmaceutical agent. The core can be located within the implant body that extends longitudinally and circumferentially around the core. The implant body can also define an aperture that exposes a first surface of the core. A method for treating a mammal to obtain a desired physiological or pharmacological effect by injecting such a drug delivery implant into a mammal in need of treatment is also disclosed.

Abstract: Formulations and intravitreal implants containing nintedanib can be used in methods for the treatment of back-of-the-eye diseases.

Abstract: Provided herein are devices and methods for treating inflammation and pain of articular joints (e.g., the knee). An implantable device includes an elongate body extending from a proximal end to a distal end, a flange disposed at the proximal end, a bore extending from an opening at the proximal end into the elongate body, one or more fixation members disposed on an outer surface of the elongate body, and a payload (e.g., a drug-polymer core) having a therapeutic agent disposed within the bore. The payload has a substantially constant surface area on an exposed portion throughout elution of the therapeutic agent after the implantable device is implanted in a body. The therapeutic agent is configured to elute using zero-order kinetics, constantly and continuously at an amount that is above a predetermined lower threshold and does not exceed a predetermined upper threshold unlike a pulse-dose injection.

Abstract: This invention discloses bioerodible devices, such as implants for delivering therapeutic agents, particularly large molecules such as proteins and antibodies, in a controlled manner. The devices comprise a porous silicon-based carrier material impregnated with the therapeutic agent. The device may be used in vitro or in vivo to deliver the therapeutic agent, preferably in a controlled fashion over an intended period of time such as over multiple days, weeks or months. The device may be used for treating or preventing conditions of a patient such as chronic diseases.

Abstract: Systems, methods, and non-transitory computer readable media can obtain a first event stream including one or more events of a first type, where each event of the first type is associated with a timestamp. A second event stream including one or more events of a second type can be obtained, where each event of the second type is associated with a timestamp. The first event stream and the second event stream can be merged to generate information associated with a metric relating to a system, based on the timestamps associated with the one or more events of the first type and the timestamps associated with the one or more events of the second type.

Abstract: An injectable drug delivery device includes a core containing one or more drugs and one or more polymers. The core may be surrounded by one or more polymer outer layers (referred to herein as “coatings,” “skins,” or “outer layers”). In certain embodiments, the device is formed by extruding or otherwise preforming a polymeric skin for a drug core. The drug core may be co-extruded with the skin, or inserted into the skin after the skin has been extruded, and possibly cured. In other embodiments, the drug core may be coated with one or more polymer coatings. These techniques may be usefully applied to fabricate devices having a wide array of drug formulations and skins that can be selected to control the release rate profile and various other properties of the drugs in the drug core in a form suitable for injection using standard or non-standard gauge needles.

Abstract: The present invention relates to sustained release drug delivery systems, medical devices incorporating said systems, and methods of use and manufacture thereof. The inventive systems feature bioerodible drug delivery devices that include biocompatible solid and biocompatible fluid compositions to achieve desired sustained release drug delivery.

Abstract: Systems, methods, and non-transitory computer readable media can obtain a first event stream including one or more events of a first type, where each event of the first type is associated with a timestamp. A second event stream including one or more events of a second type can be obtained, where each event of the second type is associated with a timestamp. The first event stream and the second event stream can be merged to generate information associated with a metric relating to a system, based on the timestamps associated with the one or more events of the first type and the timestamps associated with the one or more events of the second type.

Abstract: The invention comprises a composition comprising a bioerodible porous silicon-based carrier material wherein the carrier material carries at least one large molecule therapeutic agent and at least one amorphous sugar, optionally further comprising a crystallization inhibitor. The composition may be used in vitro or in vivo to deliver the therapeutic agent, preferably in a controlled fashion over an intended period of time such as over multiple days, weeks or months. The composition may be used for treating or preventing conditions of a patient such as chronic diseases.

Abstract: The invention provides a biodegradable drug-eluting particle useful for the delivery of diagnostic or therapeutic agents. In certain embodiments, the drug-eluting particle of the invention comprises a biodegradable porous silicon body, a reservoir formed within the porous silicon body having at least one opening to an exterior of the body, wherein the reservoir contains a therapeutic or diagnostic agent, and an agent-permeable seal disposed over the at least one opening. The invention further provides a method for treating a patient to obtain a desired local or systemic physiological or pharmacological effect comprising administering a sustained release drug delivery particle of the invention. The invention also provides methods of fabricating a drug-eluting particle for releasing therapeutic agents.

Abstract: A method and device for treating a mammalian organism to obtain a desired local or systemic physiological or pharmacological effect is provided. The method includes administering a sustained release drug delivery system to a mammalian organism in need of such treatment at an area wherein release of an effective agent is desired and allowing the effective agent to pass through the device in a controlled manner. The device includes an inner core or reservoir including the effective agent, an impermeable tube which encloses portions of the reservoir, and a permeable member at an end of the tube.

Abstract: This invention discloses bioerodible devices, such as implants for delivering therapeutic agents, particularly large molecules such as proteins and antibodies, in a controlled manner. The devices comprise a porous silicon-based carrier material impregnated with the therapeutic agent. The device may be used in vitro or in vivo to deliver the therapeutic agent, preferably in a controlled fashion over an intended period of time such as over multiple days, weeks or months. The device may be used for treating or preventing conditions of a patient such as chronic diseases.

Abstract: The invention provides a biodegradable drug-eluting particle useful for the delivery of diagnostic or therapeutic agents. In certain embodiments, the drug-eluting particle of the invention comprises a biodegradable porous silicon body, a reservoir formed within the porous silicon body having at least one opening to an exterior of the body, wherein the reservoir contains a therapeutic or diagnostic agent, and an agent-permeable seal disposed over the at least one opening. The invention further provides a method for treating a patient to obtain a desired local or systemic physiological or pharmacological effect comprising administering a sustained release drug delivery particle of the invention.

Abstract: The invention comprises a composition comprising a bioerodible porous silicon-based carrier material wherein the carrier material carries at least one large molecule therapeutic agent and at least one amorphous sugar, optionally further comprising a crystallization inhibitor. The composition may be used in vitro or in vivo to deliver the therapeutic agent, preferably in a controlled fashion over an intended period of time such as over multiple days, weeks or months. The composition may be used for treating or preventing conditions of a patient such as chronic diseases.

Abstract: The invention comprises a composition comprising a bioerodible porous silicon-based carrier material wherein the carrier material carries at least one large molecule therapeutic agent and at least one amorphous sugar, optionally further comprising a crystallization inhibitor. The composition may be used in vitro or in vivo to deliver the therapeutic agent, preferably in a controlled fashion over an intended period of time such as over multiple days, weeks or months. The composition may be used for treating or preventing conditions of a patient such as chronic diseases.

Abstract: The invention provides liquid controlled-release drug delivery compositions which gel upon injection into the body to form, in situ, controlled-release drug implants. The compositions of the invention feature a gel-forming polymer that is insoluble in water, a polyethylene glycol solvent in which the polymer is dissolved, and the drug substance to be delivered.

Abstract: This invention discloses bioerodible devices, such as implants for delivering therapeutic agents, particularly large molecules such as proteins and antibodies, in a controlled manner. The devices comprise a porous silicon-based carrier material impregnated with the therapeutic agent. The device may be used in vitro or in vivo to deliver the therapeutic agent, preferably in a controlled fashion over an intended period of time such as over multiple days, weeks or months. The device may be used for treating or preventing conditions of a patient such as chronic diseases.

Abstract: This invention discloses bioerodible delivery compositions for delivering peptide therapeutic agents. The delivery compositions comprise a porous silicon-based carrier material loaded with the therapeutic agent. The delivery compositions may be used in vitro or in vivo to deliver the therapeutic agent, preferably in a controlled fashion over an intended period of time such as over multiple days, weeks or months. The delivery compositions may be used for treating or preventing conditions of a patient such as chronic diseases.